Amylin Pharmaceuticals and Biocon Limited Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid
September 10 2009 - 4:15PM
PR Newswire (US)
Program will Focus on the Potential Treatment of Diabetes SAN DIEGO
and BANGALORE, India, Sept. 10 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) and Biocon, Limited
(NSE:BIOCON) announced today that they have entered into an
exclusive agreement to jointly develop, commercialize and
manufacture a novel peptide therapeutic for the potential treatment
of diabetes. Amylin and Biocon will collaborate to develop the
therapeutic potential of the compound and share development costs.
Research will center on Amylin's "phybrid" technology. A phybrid is
a peptide hybrid molecule that combines the pharmacological effects
of two peptide hormones into a single molecular entity. Under the
terms of the Development and Commercialization Agreement, Amylin
will provide expertise in peptide hormone development, particularly
in the area of phybrid technology, as well as metabolic disease
therapeutics. Biocon will utilize its expertise in recombinant
microbial expression to manufacture the compound and also leverage
its experience in preclinical and clinical development of diabetes
products. "This agreement fully leverages the synergistic
capabilities of the two companies," said Kiran Mazumdar-Shaw,
Chairman and Managing Director, Biocon, Ltd. "Amylin's knowledge of
peptide therapeutics and their leadership in the diabetes market,
paired with Biocon's capabilities in process development,
manufacturing and clinical development, provides this global
program with the potential to effectively bring a novel therapy to
patients living with diabetes." "This program could unleash the
potential of cutting-edge peptide science to transform the lives of
patients with diabetes," said Daniel M. Bradbury, President and
Chief Executive Officer, Amylin Pharmaceuticals. "We are pleased to
work with Biocon, a biologics innovator and world-class
manufacturing expert, and look forward to collaborating with them
on this exciting program." About Amylin Pharmaceuticals Amylin
Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN (pramlintide acetate) injection and BYETTA (exenatide)
injection. Amylin's research and development activities leverage
the Company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California. Further information about Amylin
Pharmaceuticals is available at http://www.amylin.com/. About
Biocon Limited Established in 1978, Biocon Limited is one of
India's premier biotechnology companies. Together with its group
companies, Biocon forms a fully integrated biotechnology
enterprise, specializing in biopharmaceuticals, custom research and
clinical research which deliver products and solutions to partners
and customers across the globe. Focusing on unmet medical needs in
cancer, diabetes and inflammatory diseases, Biocon offers therapies
on a platform of affordable innovation. Biocon has a strong focus
in diabetes having launched the world's first recombinant human
insulin, INSUGEN , using a Pichia based expression system in 2004
and recombinant glargine, BASALOG , in 2009. In the oncology
segment, Biocon launched India's first indigenously produced novel
monoclonal antibody BIOMAB EGFR . Biocon received the 2009
BioSingapore Asia Pacific Biotechnology Award for Best Listed
Company in the region. For more information, visit
http://www.biocon.com/. Amylin Forward-Looking Statements This
press release contains forward-looking statements about Amylin,
which involve risks and uncertainties. The Company's actual results
could differ materially from those discussed due to a number of
risks and uncertainties, including that the phybrid program
mentioned in this press release will not produce the results we
expect, our clinical trials may not start when planned and/or
confirm previous results; our preclinical studies may not be
predictive; our product candidates may not receive regulatory
approval; and inherent scientific, regulatory and other risks in
the drug development and commercialization process. These and
additional risks and uncertainties are described more fully in the
Company's most recently filed SEC documents, including its Form
10-Q. Amylin undertakes no duty to update these forward-looking
statements. Biocon Forward-Looking Statements Certain statements in
this release concerning Biocon's future growth prospects are
forward-looking statements, which are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those contemplated in such forward-looking
statements. Important factors that could cause actual results to
differ materially from our expectations include, amongst others
general economic and business conditions in India, our ability to
successfully implement our strategy, our research and development
efforts, our growth and expansion plans and technological changes,
changes in the value of the Rupee and other currency changes,
changes in the Indian and international interest rates, change in
laws and regulations that apply to the Indian and global
biotechnology and pharmaceuticals industries, increasing
competition in and the conditions of the Indian biotechnology and
pharmaceuticals industries, changes in political conditions in
India and changes in the foreign exchange control regulations in
India. Neither our company, our directors, nor any of our
affiliates have any obligation to update or otherwise revise any
statements reflecting circumstances arising after this date or to
reflect the occurrence of underlying events, even if the underlying
assumptions do not come to fruition. DATASOURCE: Amylin
Pharmaceuticals, Inc. CONTACT: Anne Erickson of Amylin
Pharmaceuticals, Inc., +1-858-754-4443, cell, +1-858-349-3195, ; or
Paula Sengupta of Biocon Limited, +91 (80) 28082225, cell, +91
98455 42838, Web Site: http://www.amylin.com/
http://www.biocon.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024